ClinicalTrials.gg
CompletedNCT03773835Updated Mar 3, 2020

A Study Evaluating Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Single IV Dose of HSK3486 Injectable Emulsion in Healthy Subjects.

A Phase 1 interventional study of HSK3486 in Anesthesia and Sedation, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Completed. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-03.

Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled May 2016, registered Dec 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Ages
18 Years to 49 Years
Sex
All
01

Study summary

his single-center, open-label, uncontrolled, and dose-escalation study evaluated the safety, tolerability, and pharmacokinetics/pharmacodynamics of single IV dose of HSK3486 injectable emulsion in healthy subjects.

02

Conditions studied

  • Anesthesia
  • Sedation
03

In context

Lead sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or females with full capacity for civil conduct, between 18 and 49 years old (inclusive);
  2. Body weight > 45 kg, and (BMI) ≥ 19 and ≤24 kg/m2;
  3. Blood pressure between 90-140/60-90 mmHg; heart rate between 60-99 bpm; body temperature between 35.8-37.5 ºC; respiration rate between 12-24 breaths per minute; SpO2 when inhaling > 95%;
  4. Normal physical examination, laboratory tests (blood routine, blood biochemistry, and urine routine), 12-Led , posteroanterior and lateral chest x-ray, and or abnormal but without clinical significance (determined by investigator); no potential difficult airway;
  5. Subjects must understand the procedures and methods of this study, and be willing to provide and to complete the trial in strict accordance with clinical trial protocol.

Exclusion criteria

Exclusion Criteria:

  1. Known sensitivity to propofol, in propofol medium and long chain fat emulsion injection, excipient in HSK3486 injectable emulsion;
  2. in general anesthesia;
  3. Received any one of the following medications or treatments prior to screening/enrollment:

    1. History of medication abuse or any signs of chronic benzodiazepines use (such as insomnia, anxiety, spasms) within 3 months prior to screening, or a positive urine medication test (during screening or at baseline);
    2. Participated in clinical trials involving any medications or medical devices within 3 months prior to screening, or participated in 3 or more drug clinical trials within the past year;
  4. History or evidence of increased risk of sedation or anesthesia, such as cardiovascular disease, respiratory disease, cerebrovascular disease, gastrodintestinal disease and other system disease prior to the screening and/or baseline period;
  5. Laboratory results that meet any of the following during screening/enrollment:

    1. Positive for , , or ;
    2. Abnormal hepatic or renal function confirmed after re-examination;

      • or AST > ;
      • Creatinine > ULN;
  6. History of smoking for more than 3 weeks and/or respiratory irritation caused by smoking within 3 months prior to screening;
  7. History of alcohol abuse within 3 months prior to screening or a positive alcohol test (baseline);
  8. Women who are pregnant or breastfeeding; women of or men who are unwilling to use during the trial;
  9. Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    HSK3486

    0.15mg/kg, 0.40mg/kg, 0.60mg/kg, 0.90mg/kg,

    Drug: HSK3486

Interventions

  • Mmanual IV bolus injection completed in 1 minute.

06

What researchers measure

Primary outcomes

  1. Apnea

    No movement of chest wall and cessation of end-tidal carbon dioxide waveform \> 15 seconds.

    Time frame: First dose of study drug on day 1

  2. Safety by measurement of Adverse Events

    Time frame: First dose of study drug on day 1

Secondary outcomes

  1. Modified observer's assessment of alertness/sedation(MOAA/S)

    Observe the change of modified observer's assessment of alert /sedation during the whole trial

    Time frame: From first dose of study drug until fully alert on day 1

  2. Bispectral index (BIS)

    Time frame: From first dose of study drug until fully alert on day 1

  3. Median effective dose (ED50)

    Time frame: From first dose of study drug until fully alert on day 1

  4. Peak concentration (Cmax)

    Time frame: From the start of administration to 48 hours after administration

  5. Time to plasma peak concentration(Tmax)

    Time frame: From the start of administration to 48 hours after administration

  6. Terminal elimination half life (t1/2z) and mean residence time (MRT)

    Time frame: From the start of administration to 48 hours after administration

  7. Mean residence time (MRT)

    Time frame: From the start of administration to 48 hours after administration

  8. Area Under the Curve (AUC0-30min, AUC0-1h, AUC0-last, and AUC0-inf)

    Time frame: From the start of administration to 48 hours after administration

  9. Total clearance (CL)

    Time frame: From the start of administration to 48 hours after administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Aug 2016, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2018
First posted
Dec 12, 2018
StartActual
May 2016
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Last update
Mar 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03773835
Responsible party
Sponsor
First posted
Dec 12, 2018
Start date
May 2016
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Mar 3, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion